OXBDF - Oxford Biomedica reported FY prelim revenue growth of 37%

Oxford Biomedica (OXBDF) reported prelim total revenues of £87.7M (+37% Y/Y) for the year ended Dec.31, 2020.Operating EBITDA profit of £7.3M (2019: £5.2M loss), marginally above guided range; operating loss incurred of £5.7 million (2019: £14.5M loss).Cash of £46.7M at Dec. 31 2020 (2019: £16.2M) and £65.9M at Mar. 31 2021."We not only secured major new partnerships, brought the Oxbox manufacturing facility online in record time and responded to the challenges of the pandemic, but the team has also been able to rapidly work with AstraZeneca to provide a vaccine solution for COVID-19," CEO John Dawson commented.

For further details see:

Oxford Biomedica reported FY prelim revenue growth of 37%